IDH mutation has emerged as a marker of better prognosis in low- and high-grade gliomas, in adults, and a mutation in EGFR, EGFRvIII, has also been studied as a biomarker related to tumour response and relapse as well as a potential therapeutic target [6]. The gene discussed is EGFR; the disease is neoplasm.